{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:28:55Z","timestamp":1790803735325,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicalnutritionjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Nutrition"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.clnu.2025.04.027","type":"journal-article","created":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T23:34:22Z","timestamp":1746056062000},"page":"76-82","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Dietary intake remains unchanged while nutritional status improves in children and adults with cystic fibrosis on Elexacaftor\/Tezacaftor\/Ivacaftor"],"prefix":"10.1016","volume":"50","author":[{"given":"R.","family":"Enaud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Languepin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Lagarrigue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Arrouy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Macey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Bui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Dupuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Roditis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Flumian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5425-7352","authenticated-orcid":false,"given":"E.","family":"Mas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Mittaine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clnu.2025.04.027_bib1","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1016\/S0140-6736(09)60327-5","article-title":"Cystic fibrosis","volume":"373","author":"O'Sullivan","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.clnu.2025.04.027_bib2","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nrgastro.2015.226","article-title":"Cystic fibrosis from the gastroenterologist's perspective","volume":"13","author":"Ooi","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.clnu.2025.04.027_bib3","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1067\/mpd.2000.107891","article-title":"Longitudinal relationship among growth, nutritional status, and pulmonary function in children with cystic fibrosis: analysis of the Cystic Fibrosis Foundation National CF Patient Registry","volume":"137","author":"Zemel","year":"2000","journal-title":"J Pediatr"},{"key":"10.1016\/j.clnu.2025.04.027_bib4","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.clnu.2023.12.017","article-title":"ESPEN-ESPGHAN-ECFS guideline on nutrition care for cystic fibrosis","volume":"43","author":"Wilschanski","year":"2024","journal-title":"Clin Nutr"},{"key":"10.1016\/j.clnu.2025.04.027_bib5","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1055\/s-0039-1696726","article-title":"Growth and nutrition in cystic fibrosis","volume":"40","author":"Brownell","year":"2019","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.clnu.2025.04.027_bib6","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.clnu.2025.04.027_bib7","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clnu.2025.04.027_bib8","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jcf.2021.11.012","article-title":"Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis","volume":"21","author":"Petersen","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.clnu.2025.04.027_bib9","first-page":"13","article-title":"Body Mass Index variations: centiles from birth to 87 years","volume":"45","author":"Rolland-Cachera","year":"1991","journal-title":"Eur J Clin Nutr"},{"key":"10.1016\/j.clnu.2025.04.027_bib10","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.tjnut.2024.01.029","article-title":"Consistency of the initial and updated version of the Nutri-Score with food-based dietary guidelines: a French perspective","volume":"154","author":"Sarda","year":"2024","journal-title":"J Nutr"},{"key":"10.1016\/j.clnu.2025.04.027_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/nu16193293","article-title":"Impact of Elexacaftor-Tezacaftor-Ivacaftor therapy on body composition, dietary intake, biomarkers, and quality of life in people with cystic fibrosis: a prospective observational study","volume":"16","author":"Hevilla","year":"2024","journal-title":"Nutrients"},{"key":"10.1016\/j.clnu.2025.04.027_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/nu16183103","article-title":"Is obesity a problem in new cystic fibrosis treatments?","volume":"16","author":"Solis-Garcia","year":"2024","journal-title":"Nutrients"},{"key":"10.1016\/j.clnu.2025.04.027_bib13","doi-asserted-by":"crossref","first-page":"3632","DOI":"10.1002\/ppul.27272","article-title":"Effects on growth, weight and body composition after CFTR modulators in children with cystic fibrosis","volume":"59","author":"Lopez Cardenes","year":"2024","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.clnu.2025.04.027_bib14","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on lung function, nutritional status, pulmonary exacerbation frequency and sweat chloride in people with cystic fibrosis: real-world evidence from the German CF Registry","volume":"32","author":"Sutharsan","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.clnu.2025.04.027_bib15","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.jcf.2023.06.010","article-title":"Body mass index and nutritional intake following Elexacaftor\/Tezacaftor\/Ivacaftor modulator therapy in adults with cystic fibrosis","volume":"22","author":"Caley","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.clnu.2025.04.027_bib16","doi-asserted-by":"crossref","first-page":"6900","DOI":"10.3390\/jcm11236900","article-title":"Cystic fibrosis patients with F508del\/Minimal function genotype: laboratory and nutritional evaluations after one year of Elexacaftor\/Tezacaftor\/Ivacaftor treatment","volume":"11","author":"Carnovale","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.clnu.2025.04.027_bib17","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1007\/s10620-012-2209-1","article-title":"Intestinal pH and gastrointestinal transit profiles in cystic fibrosis patients measured by wireless motility capsule","volume":"58","author":"Gelfond","year":"2013","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.clnu.2025.04.027_bib18","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jpeds.2018.05.018","article-title":"Energy balance and mechanisms of weight gain with ivacaftor treatment of cystic fibrosis gating mutations","volume":"201","author":"Stallings","year":"2018","journal-title":"J Pediatr"},{"key":"10.1016\/j.clnu.2025.04.027_bib19","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-36364-6","article-title":"Impact of CFTR modulation with ivacaftor on Gut Microbiota and intestinal inflammation","volume":"8","author":"Ooi","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.clnu.2025.04.027_bib20","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jcf.2023.10.001","article-title":"Reduction in abdominal symptoms (CFAbd-Score), faecal M2-pyruvate-kinase and calprotectin over one year of treatment with Elexacaftor-Tezacaftor-Ivacaftor in people with CF aged >\/=12 years - the RECOVER study","volume":"23","author":"Mainz","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.clnu.2025.04.027_bib21","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1097\/MPG.0000000000002864","article-title":"Reduced intestinal inflammation with Lumacaftor\/Ivacaftor in adolescents with cystic fibrosis","volume":"71","author":"Tetard","year":"2020","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.clnu.2025.04.027_bib22","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.01935-23","article-title":"Longitudinal profiling of the intestinal microbiome in children with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor","volume":"15","author":"Reasoner","year":"2024","journal-title":"mBio"},{"key":"10.1016\/j.clnu.2025.04.027_bib23","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/jpn3.12350","article-title":"Premodulator microbiome alterations associated with postmodulator growth outcomes in pediatric cystic fibrosis: can we predict outcomes?","volume":"79","author":"Sanville","year":"2024","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.clnu.2025.04.027_bib24","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1159\/000538606","article-title":"Improved nutritional outcomes and gastrointestinal symptoms in adult cystic fibrosis patients treated with Elexacaftor\/Tezacaftor\/Ivacaftor","volume":"42","author":"Stastna","year":"2024","journal-title":"Dig Dis"},{"key":"10.1016\/j.clnu.2025.04.027_bib25","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.jcf.2023.09.005","article-title":"Changes in fecal elastase-1 following initiation of CFTR modulator therapy in pediatric patients with cystic fibrosis","volume":"22","author":"Stephenson","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.clnu.2025.04.027_bib26","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1002\/ppul.26823","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on lipid and fat-soluble vitamin levels and association with body mass index","volume":"59","author":"Patel","year":"2024","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.clnu.2025.04.027_bib27","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jcf.2023.11.005","article-title":"Decline in HbA1c during the first year of elexacaftor\/tezacaftor\/ivacaftor treatment in the Danish cystic fibrosis cohort: short title: decline in HbA1c after elexacaftor\/tezacaftor\/ivacaftor treatment","volume":"23","author":"Nielsen","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.clnu.2025.04.027_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2024.107664","article-title":"Long-term therapy with CFTR modulators consistently improves glucose metabolism in adolescents and adults with cystic fibrosis","volume":"228","author":"Cohen","year":"2024","journal-title":"Respir Med"},{"key":"10.1016\/j.clnu.2025.04.027_bib29","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2022.2156254","article-title":"Diet and the gut-lung axis in cystic fibrosis - direct & indirect links","volume":"15","author":"McKay","year":"2023","journal-title":"Gut Microbes"},{"key":"10.1016\/j.clnu.2025.04.027_bib30","doi-asserted-by":"crossref","first-page":"9465","DOI":"10.1038\/s41598-024-59622-2","article-title":"Elexacaftor\/tezacaftor\/ivacaftor influences body composition in adults with cystic fibrosis: a fully automated CT-based analysis","volume":"14","author":"Westholter","year":"2024","journal-title":"Sci Rep"}],"container-title":["Clinical Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0261561425001219?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0261561425001219?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T16:57:54Z","timestamp":1762275474000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0261561425001219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":30,"alternative-id":["S0261561425001219"],"URL":"https:\/\/doi.org\/10.1016\/j.clnu.2025.04.027","relation":{},"ISSN":["0261-5614"],"issn-type":[{"value":"0261-5614","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dietary intake remains unchanged while nutritional status improves in children and adults with cystic fibrosis on Elexacaftor\/Tezacaftor\/Ivacaftor","name":"articletitle","label":"Article Title"},{"value":"Clinical Nutrition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clnu.2025.04.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}